We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the Intel Business Challenge Europe website. However, if you would like to, you can change your cookie settings at any time.
Catheter associated urinary tract infections affects 1.2M of the 8M undergoing urinary tract catherization in the US and EU combined, accounting for more than 40% of all hospital acquired cases. In 2012 it resulted in 26,000 reported deaths. Associated hospital costs total 600M USD every year in each region. The infection is the result of bacterial adhesion causing infection including implant malfunction. Currently, there is no effective coating that prevents such adhesion and the later effects.
BioRepeller is using an innovative and simple coating technique that prevents bio-adhesion onto material surfaces. It eliminates adhesion for more than 36 days, at least four times longer than current coatings.
An aging population and rising incidence of urological problems drives growth in the urological catheter market. In 2012 the total EU and US market was worth 1.2B USD and is expected to surpass 2B USD by 2017. An attractive market for BioRepeller.
